Table 2 Included study characteristics
Study author | Year | Country | Study setting | Prognostic or diagnostic | N | Sepsis definition | PC assay | Prognostic outcome | Diagnostic outcome |
|---|---|---|---|---|---|---|---|---|---|
Chornenki [28] | 2020 | Canada | MC, ICU | Diagnostic | 357 | Sepsis-3 | ELISA | – | Sepsis + DIC |
Masuda [27] | 2020 | Japan | SC, ED | Diagnostic | 107 | Sepsis-1 | – | – | Sepsis + DIC |
Ishikura [29] | 2014 | Japan | SC, ED | Diagnostic | 84 | Sepsis-1 | Coagulation Analyzer | – | Sepsis |
Mihajlovic [30] | 2016 | Serbia | SC, ED, IDC | Prognostic | 150 | Sepsis-2 | Coagulation Analyzer | 28-day mortality | – |
Dwivedi [31] | 2012 | Canada | MC, ICU | Prognostic | 80 | Sepsis-2 | ELISA | Mortality | – |
Umemura [32] | 2016 | Japan | SC, ED | Both | 79 | Sepsis-1 | Coagulation Analyzer | Mortality | Sepsis + DIC |
Liaw [33] | 2019 | Canada | MC, ICU | Prognostic | 356 | Sepsis-3 | ELISA | 28-day mortality | – |
Lorente [34] | 1993 | Spain | ICU | Both | 48 | Sepsis-1 | Immunoelectro-phoresis | 28-day mortality | Septic shock |
Walborn [35] | 2020 | USA | ICU | Both | 103 | Sepsis-1 | Coagulation Analyzer | 28-day mortality | Sepsis + DIC |
Koyama [36] | 2014 | Japan | SC, ICU | Both | 77 | Sepsis-2 | Coagulation Analyzer | 28-day mortality | Sepsis + DIC |
Shapiro [37] | 2009 | USA | MC, ED | Both | 971 | Sepsis-1 | ELISA | In-hospital mortality | Severe Sepsis |
Karamarkovic [38] | 2005 | Serbia | SC | Both | 59 | Sepsis-1 | Coagulation Analyzer | Mortality | Surgical sepsis |